On January 15, 2026, Science & Humans announced that it had raised $10 million of Series A financing. This amount includes $7 million in equity and $3 million in venture debt. Pender Ventures led the equity round with participation from Well Health Technologies, Michele Romanow and undisclosed U.S. healthcare investors, and the venture debt was provided by CIBC Innovation Banking.
Science & Humans is a Toronto-based healthtech company whose software offers personalized treatment for Canadian men and women with hormone health imbalances, connecting them to specialists to diagnose and address these issues.
It originally launched as a B2C business and plans to put this Series A financing towards the national expansion of their B2B model. In addition, they hope to expand their tech and AI capabilities, aiming to build an integrated pharmacy and lab system.
Pender Ventures is a Vancouver-based venture capital investor with a focus on healthtech and B2B technology.
Osler, Hoskin and Harcourt LLP represented Pender Ventures with a team consisting of Mark Longo, Andrew Irwin and Rebecca Garner (Emerging and High Growth Companies).
Key Contact
Partner, Emerging and High Growth Companies, Vancouver
Team
Counsel, Emerging and High Growth Companies, Toronto
Associate, Emerging and High Growth Companies, Vancouver
